PROTHENA CORP PUBLIC LTD CO - 10-Q Filing
Prothena Corp filed its Q1 2026 10-Q report with the SEC on April 30, 2026, disclosing unaudited financial results for the quarter ended March 31, 2026. The filing outlines ongoing operations related to drug development programs including Birtamimab (NEOD001), PRX012, and PRX019, as well as collaborations with Roche, Bristol Myers Squibb, and Novo Nordisk.
Tickers: $PRTA